– USA, MA – ReForm Biologics, Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Dr. John Yee, MD, MPH to its Board of Directors.
“Dr. John Yee is a purpose-driven medical leader with a passion for improving patient outcomes who has more than 20 years of drug development experience in both early-stage biotechnology companies and at established pharmaceutical companies,” said Executive Chairman, Jim Sherblom. “John’s considerable record of accomplishment will be invaluable to ReForm as we develop a pipeline of reformulated biotherapeutics that will be better tolerated by vulnerable patients particularly the elderly and children. On behalf of all of us at ReForm, I welcome John to the Board and we look forward to his contributions.”
About Dr. John Yee
Dr. Yee is currently CMO at Sobi North America. Before joining Sobi, he served as SVP, Medical Affairs at Flexion Therapeutics, SVP and Global Head of Medical Affairs at Vertex Pharmaceuticals, and VP, Medical Affairs, Safety and Operations at Intarcia Therapeutics.
From 2011 to 2016, Dr. Yee was at AstraZeneca Pharmaceuticals, where he served as VP, US Head Medical Officer, and VP and Head of Medical Affairs for the US Diabetes franchise. Dr. Yee began his industry career at Genzyme Corporation in 2003 as Director, Global Medical Programs, and later served in other leadership roles, including VP, Global Medical Affairs and VP, Global Head, Evidence-Based Medicine and Health Outcomes Research.
Dr. Yee earned his MD at Harvard Medical School and graduated from the T.H. Chan School of Public Health at Harvard with an MPH in Health Care Management. He completed his pediatric residency and fellowship training at Boston Children’s Hospital. Before joining the industry, John held leadership roles at Boston Children’s Hospital and was a faculty member at Harvard Medical School.
“ReForm is committed to changing the characteristics of biological medicines so that they are more easily administered and better tolerated by patients,” said Dr. Yee. “Currently, most biologics are administered as intravenous infusions which can be time-consuming as well as uncomfortable for patients. By reformulating biologic medicines to improve viscosity and stability, these biologics could be administered by subcutaneous injection, a potentially much more convenient process that could be less painful, particularly for children and older patients. I am excited to join ReForm as the company advances its programs to the clinic.”
About ReForm Biologics, Inc.
ReForm Biologics’ mission is to develop improved biologic formulations derived from our proprietary, patented technology platform to enhance patients’ lives, particularly for fragile populations such as children and the elderly. We are doing this by improving the viscosity and stability of known biologics, with our own formulations as well as for those of other biopharmaceutical companies to make their medicines gentler for patients.
For more information: https://reformbiologics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
